pSivida and Pfizer Amend Agreement to Focus Solely on Development of Sustained-Release Implant to Deliver Latanoprost

Drug delivery company pSivida Corp PSDV today announced it amended and restated its Research and Development Agreement with Pfizer Inc. PFE to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma. The proposed implant is a bioerodible version of pSivida's proprietary Durasert technology system and is designed to be injected into the subconjunctival space of the eye.